Jaime Calvo-Alén1, Indalecio Monteagudo2, Georgina Salvador3, Tomás R Vázquez-Rodríguez4, Juan V Tovar-Beltrán5, Paloma Vela6, Francisco Maceiras7, Sagrario Bustabad8, José A Román-Ivorra9, Consuelo Díaz-Miguel10, José Rosas11, Enrique Raya12, Loreto Carmona13, Luis Cea-Calvo14, María J Arteaga14, Sabela Fernández14, Carlos Marras15. 1. Hospital Txagorritxu, Araba, Vitoria, Spain. 2. Hospital Universitario Gregorio Marañón, Madrid, Spain. indalecio.monteagudo@salud.madrid.org. 3. Hospital Universitario Mutua de Terrassa, Barcelona, Spain. 4. Hospital Universitario Lucus Augusti, Lugo, Spain. 5. Hospital Universitario de Elche, Alicante, Spain. 6. Hospital Universitario de Alicante, Spain. 7. Complexo Universitario de Vigo-XXVI, Spain. 8. Hospital Universitario de Canarias, Tenerife, Spain. 9. Hospital Universitario y Politécnico La Fe, Valencia, Spain. 10. Hospital Universitario Ramón y Cajal, Madrid, Spain. 11. Hospital Marina Baixa, Villajoyosa, Alicante, Spain. 12. Hospital Universitario San Cecilio de Granada, Spain. 13. Instituto de Salud Musculoesquelética, Madrid, Spain. 14. Medical Affairs, Merck Sharp & Dohme of Spain. 15. Hospital Universitario Virgen de Arrixaca, Murcia, Spain.
Abstract
OBJECTIVES: To evaluate non-adherence to prescribed subcutaneous biologicals in rheumatoid arthritis (RA) patients in Spain. METHODS: ARCO (Study on Adherence of Rheumatoid Arthritis patients to SubCutaneous and Oral Drugs) was a multicentre, non-interventional retrospective study involving 42 rheumatology clinics from representative hospitals throughout Spain. The primary objective was to assess the percentage of patients (aged ≥18 years with an established RA diagnosis) with non-adherence to prescribed subcutaneous biologicals using clinical records and hospital pharmacy dispensing logs as the primary information sources. Adherence was assessed using the Medication Possession Ratio (MPR). Additionally, patients completed the Morisky-Green Medication Adherence Questionnaire. RESULTS: A total of 364 patients (77.5% females, mean age 54.9 years, median RA duration since diagnosis 7.8 years) were enrolled in ARCO. Non-adherence (MPR ≤80%) was reported in 52/363 evaluable patients (14.3%), and was lower in patients receiving initial monthly drug administration (6.4%) than with weekly (17.4%; p=0.034) or every two weeks (14.4%; p=0.102) administration. By multivariate analysis, non-adherence was positively associated with RA duration above the median and with using induction doses. Monthly administration, compared to weekly administration, was inversely associated with non-adherence. Age, gender, order of administration, and changes in the interval of administration, showed no association with non-adherence. Compared with the MPR, the Morisky-Green questionnaire performed poorly in detecting non-adherence. CONCLUSIONS: Non-adherence to the prescribed subcutaneous biological drug occurred in 14.3% of patients with RA. Patients using the most convenient administration period (i.e. monthly) had better adherence than those using more frequent dosing schedules.
OBJECTIVES: To evaluate non-adherence to prescribed subcutaneous biologicals in rheumatoid arthritis (RA) patients in Spain. METHODS: ARCO (Study on Adherence of Rheumatoid Arthritispatients to SubCutaneous and Oral Drugs) was a multicentre, non-interventional retrospective study involving 42 rheumatology clinics from representative hospitals throughout Spain. The primary objective was to assess the percentage of patients (aged ≥18 years with an established RA diagnosis) with non-adherence to prescribed subcutaneous biologicals using clinical records and hospital pharmacy dispensing logs as the primary information sources. Adherence was assessed using the Medication Possession Ratio (MPR). Additionally, patients completed the Morisky-Green Medication Adherence Questionnaire. RESULTS: A total of 364 patients (77.5% females, mean age 54.9 years, median RA duration since diagnosis 7.8 years) were enrolled in ARCO. Non-adherence (MPR ≤80%) was reported in 52/363 evaluable patients (14.3%), and was lower in patients receiving initial monthly drug administration (6.4%) than with weekly (17.4%; p=0.034) or every two weeks (14.4%; p=0.102) administration. By multivariate analysis, non-adherence was positively associated with RA duration above the median and with using induction doses. Monthly administration, compared to weekly administration, was inversely associated with non-adherence. Age, gender, order of administration, and changes in the interval of administration, showed no association with non-adherence. Compared with the MPR, the Morisky-Green questionnaire performed poorly in detecting non-adherence. CONCLUSIONS: Non-adherence to the prescribed subcutaneous biological drug occurred in 14.3% of patients with RA. Patients using the most convenient administration period (i.e. monthly) had better adherence than those using more frequent dosing schedules.
Authors: Manuel Pombo-Suarez; Carlos Sanchez-Piedra; Blanca Garcia-Magallón; Ana Pérez-Gómez; Sara Manrique-Arija; Raquel Martín-Doménech; María Colazo; Cristina Campos; José Campos; Javier Del Pino-Montes; Maria J Arteaga; Luis Cea-Calvo; Federico Díaz-González; Juan J Gómez-Reino Journal: Clin Rheumatol Date: 2021-04-27 Impact factor: 2.980
Authors: Kim Lauper; Denis Mongin; Florenzo Iannone; Eirik Klami Kristianslund; Tore K Kvien; Dan Nordström; Karel Pavelka; Manuel Pombo-Suarez; Ziga Rotar; Maria Jose Santos; Catalin Codreanu; Galina Lukina; Delphine S Courvoisier; Cem Gabay Journal: RMD Open Date: 2018-11-05
Authors: E H Vogelzang; R C F Hebing; M T Nurmohamed; A W R van Kuijk; J W F Kruijff; M J l'Ami; C L M Krieckaert; G Wolbink Journal: PLoS One Date: 2018-10-09 Impact factor: 3.240